💊 Rapamycin Clinical Trial Aging Biomarker Simulator

Surrogate Endpoints in Aging Trials

Placeholder: short sentence on why surrogate markers matter for aging trials.

• 2–5 yr: Typical trial length (Placeholder note)
• 20+ yr: Full endpoint wait (Placeholder note)
• 6–10: Surrogate markers used (Placeholder note)
• Partial: Regulatory acceptance (Placeholder note)

Why surrogates are needed

Placeholder short paragraph describing surrogate endpoint rationale.

Placeholder highlight callout for stage one.

Epigenetic Clocks and DNA Methylation Age

Placeholder: short sentence on epigenetic clock biomarker use.

• Horvath, GrimAge: Clock models (Placeholder note)
• ~350–1000: CpG sites used (Placeholder note)
• $150–300: Assay cost (Placeholder note)
• ~1–3 yr: Reported effect (Placeholder note)

How the clock is measured

Placeholder short paragraph on epigenetic clock methodology.

Placeholder highlight callout for stage two.

Inflammatory Marker Panel Tracking

Placeholder: short sentence on inflammatory marker monitoring.

• CRP, IL-6, TNF-α: Markers tracked (Placeholder note)
• Every 3 mo: Sampling interval (Placeholder note)
• ↓ modest: Rapamycin arm change (Placeholder note)
• ELISA/Luminex: Assay type (Placeholder note)

Panel composition and trend

Placeholder short paragraph on inflammatory panel behavior.

Placeholder highlight callout for stage three.

Physical Function Composite Score

Placeholder: short sentence on physical function composite scoring.

• Grip, gait, balance: Components (Placeholder note)
• 0–100: Score range (Placeholder note)
• Every 6 mo: Test frequency (Placeholder note)
• ±8 pts: Typical variance (Placeholder note)

Composite score construction

Placeholder short paragraph on function score construction.

Placeholder highlight callout for stage four.

Biomarker Change vs Clinical Outcome Gap

Placeholder: short sentence on the gap between biomarker and real outcomes.

• Few: Validated surrogates (Placeholder note)
• Weak–moderate: Correlation strength (Placeholder note)
• Years later: Outcome confirmation (Placeholder note)
• High: Risk of overreliance (Placeholder note)

Interpreting the gap

Placeholder short paragraph on surrogate-outcome gap interpretation.

Placeholder highlight callout for stage five.